How would you feel if artificial intelligence (AI) played a role in your healthcare decisions? Should AI be used in healthcare? And who is to blame if it goes wrong? How does it work? That’s exactly what we want to find out, as we have collaborated with a group of artists to design a brand-new audience-centric scenario experience that is open for all to participate in.
A major new consortium led by University College London Hospitals NHS Foundation Trust (UCLH) and UCL has been awarded £6.8 million by the National Institute of Health Research (NIHR) to conduct the largest clinical study of long COVID over the next two years. As countries around the world struggle
A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai has begun at UCLH with participants now being screened.
The first patient in the world has been dosed at the NIHR UCLH Clinical Research Facility (CRF) in a first-in-human trial of a new drug for the rare disease classical homocystinuria.
A UCLH-led trial for patients with brain cancer has recruited more UK participants than ever before for a study of its kind.
UCLH, UCL and spinout company Odin Vision have used artificial intelligence (AI) to help detect early signs of oesophageal cancer in a global first.
A trial of a new version of the AstraZeneca vaccine is to start at UCLH to see if it is effective against the Covid-19 variant first identified in South Africa.
A UCL team want to hear from researchers across the UK about their experience of involving patients and the public in rapid qualitative research.
A UCL report published today sets out a new framework and recommendations on how to reduce health inequities across the UK and ‘build back fairer’ following the pandemic.
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to research in which UCLH played a key role.
Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains.
A UCLH team that developed a live bed management tool during the Covid surge in London have been named finalists for a national health data award.
UCLH and UCL are part of an international consortium awarded a substantial prize to further develop an innovative infectious disease outbreak detection system.
More than nine in ten patients taking part in research at UCLH would consider doing so again and felt valued for their participation, according to a national survey.
Presence of tumour DNA in the blood – a biomarker or indicator of disease first identified by a BRC-supported consortium – can predict which cancer patients are most likely to relapse after having a tumour surgically removed and most likely to benefit from immunotherapy.